Literature DB >> 23243213

Mineral metabolites and CKD progression in African Americans.

Julia J Scialla1, Brad C Astor, Tamara Isakova, Huiliang Xie, Lawrence J Appel, Myles Wolf.   

Abstract

CKD progresses more rapidly to ESRD among African Americans compared with Caucasians. Disordered mineral metabolism is more severe among African Americans with CKD, which might partially explain the accelerated progression of their kidney disease. Here, using data from the African American Study of Kidney Disease and Hypertension, we evaluated longitudinal changes in serum levels of fibroblast growth factor-23 (FGF23), parathyroid hormone (PTH), phosphate, and 25-hydroxyvitamin D in a subset of 420 participants followed for a median of 4 years. We also examined the association of baseline levels of mineral metabolites with risk for ESRD or death in 809 participants. FGF23, PTH, and phosphate levels rose over time; participants with faster rates of decline in measured GFR had the greatest increases in these parameters (P<0.01 for each). Higher baseline levels of FGF23, PTH, and phosphate each associated with increased risk for ESRD or death independent of GFR. FGF23 exhibited a dose-response relationship with outcomes (HR=1.30 per doubling, 95% CI=1.15-1.47; HR=2.24 for highest compared with lowest quartile, 95% CI=1.39-3.60), whereas PTH and phosphate showed nonlinear relationships. Vitamin D insufficiency (<30 ng/ml) was present in 95% of participants, but lower levels did not independently associate with outcomes. Using death-censored ESRD as the outcome produced qualitatively similar results. In conclusion, abnormalities of mineral metabolism worsen with progressive CKD and associate with higher risk for ESRD among African Americans with hypertensive nephrosclerosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23243213      PMCID: PMC3537219          DOI: 10.1681/ASN.2012070713

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  37 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.

Authors:  Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix
Journal:  Ann Intern Med       Date:  2010-05-18       Impact factor: 25.391

3.  Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.

Authors:  Adeera Levin; Ognjenka Djurdjev; Monica Beaulieu; Lee Er
Journal:  Am J Kidney Dis       Date:  2008-10       Impact factor: 8.860

4.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

5.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Authors:  Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress
Journal:  Lancet       Date:  2010-11-06       Impact factor: 79.321

6.  Intensive blood-pressure control in hypertensive chronic kidney disease.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

7.  Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction.

Authors:  Antonio Bellasi; Marcora Mandreoli; Leopoldo Baldrati; Matteo Corradini; Pierpaolo Di Nicolò; Giulio Malmusi; Antonio Santoro
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-10       Impact factor: 8.237

8.  Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease.

Authors:  C P Kovesdy; S Ahmadzadeh; J E Anderson; K Kalantar-Zadeh
Journal:  Kidney Int       Date:  2008-03-12       Impact factor: 10.612

9.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl       Date:  2009-08       Impact factor: 10.545

Review 10.  Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.

Authors:  Rajiv Agarwal
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-28       Impact factor: 8.237

View more
  50 in total

Review 1.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

2.  Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.

Authors:  Steven Fishbane; Geoffrey A Block; Lisa Loram; John Neylan; Pablo E Pergola; Katrin Uhlig; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2017-01-12       Impact factor: 10.121

3.  Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.

Authors:  Rupal Mehta; Xuan Cai; Jungwha Lee; Julia J Scialla; Nisha Bansal; James H Sondheimer; Jing Chen; L Lee Hamm; Ana C Ricardo; Sankar D Navaneethan; Rajat Deo; Mahboob Rahman; Harold I Feldman; Alan S Go; Tamara Isakova; Myles Wolf
Journal:  JAMA Cardiol       Date:  2016-08-01       Impact factor: 14.676

4.  Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.

Authors:  Giovanni Tripepi; Barbara Kollerits; Daniela Leonardis; Mahamut Ilker Yilmaz; Maurizio Postorino; Danilo Fliser; Francesca Mallamaci; Florian Kronenberg; Carmine Zoccali
Journal:  J Am Soc Nephrol       Date:  2014-08-22       Impact factor: 10.121

Review 5.  Dietary Phosphorus Intake and the Kidney.

Authors:  Alex R Chang; Cheryl Anderson
Journal:  Annu Rev Nutr       Date:  2017-06-14       Impact factor: 11.848

6.  Association of Serum Phosphorus Concentration with Mortality and Graft Failure among Kidney Transplant Recipients.

Authors:  Hee Jung Jeon; Yong Chul Kim; Seokwoo Park; Clara Tammy Kim; Jongwon Ha; Duck Jong Han; Jieun Oh; Chun Soo Lim; In Mok Jung; Curie Ahn; Yon Su Kim; Jung Pyo Lee; Young Hoon Kim
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 8.237

7.  Serum fibroblast growth factor-23 is associated with incident kidney disease.

Authors:  Casey M Rebholz; Morgan E Grams; Josef Coresh; Elizabeth Selvin; Lesley A Inker; Andrew S Levey; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Harold I Feldman; Chi-Yuan Hsu; Pamela L Lutsey
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

8.  Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting.

Authors:  Alex R Chang; Morgan E Grams
Journal:  Am J Kidney Dis       Date:  2014-06-14       Impact factor: 8.860

9.  Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Authors:  Anthony A Portale; Myles S Wolf; Shari Messinger; Farzana Perwad; Harald Jüppner; Bradley A Warady; Susan L Furth; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-25       Impact factor: 8.237

10.  Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.

Authors:  Julia J Scialla; Rulan S Parekh; Joseph A Eustace; Brad C Astor; Laura Plantinga; Bernard G Jaar; Tariq Shafi; Josef Coresh; Neil R Powe; Michal L Melamed
Journal:  Am J Nephrol       Date:  2015-08-20       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.